AgingResearch.NewsJoin free

Qiagen Manchester

Company

Qiagen Manchester develops one asset, in phase 2 (NEU-411 in early Parkinson disease). Mostly small molecule acting on autophagy and LRRK2.

1
Asset
Furthest stage
Phase 2
0
Trials
0
Signals

Pipeline

1

  • NEU-411

    Small molecule LRRK2 inhibitor to reduce pathogenic kinase activity in Parkinson's disease

    Phase 2, Small molecule, Autophagy, LRRK2, early Parkinson disease, idiopathic Parkinson disease, Partner

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms2
  • Trials1
  • Similar companies6

Intelligence